Navigating Choices: Mosaic Embryos

A matter of choice? Patient decision-making and support in non-euploid embryo transfers. Viñals Gonzalez X, Akompey K, Sen Gupta S, Nicholls J. Human Fertility 2024;27(1):2431118.

Online survey111 people analysedQualitative themesTreated 2016–2023Open access
One community

People were recruited through a single online mosaic-embryo support group. Most were White, university-educated and treated in the USA. The results show patterns in these experiences, not how every patient feels.

Two terms worth knowing

What is PGT-A?

A few cells are taken from the embryo and checked for chromosome numbers. Think of your genetic material as books on a shelf: PGT-A doesn’t read the books for typos, it just counts them.

What is mosaicism?

Some of the embryo’s cells are normal and some are not, all in the same embryo.

Illustration only. Green cells are normal, terracotta cells are not.

What people told us

29.1%said mosaicism was discussed before testing
59.5%felt unsupported by their clinic in making decisions
3.98×more likely to feel empowered when they could discuss what the results mean

Many people ended up researching alone, using medical papers, peers, private genetic counsellors and social media groups. Some had to push their clinic to transfer a mosaic embryo, and described the emotional toll.

I wish PGT-A was explained as not an exact science.Participant #8

Questions to ask your clinic

Ask explicitly

  • Does my clinic report mosaicism?
  • What does it mean for my embryo?
  • What are the risks and success rates?

Add outside support

Genetic counselling, peer-reviewed publications and reliable charities can fill gaps in what your clinic tells you.

Consider a second opinion

If your care team is reluctant to discuss or transfer mosaic embryos, a second view may help. Ask yourself whether the clinic invited your questions.

What was discussed before PGT-A

Share of respondents who recalled each topic being covered by their clinic.

What is PGT-A
95.1%
Results by age
49.5%
Risk of harm to embryo
43.7%
Where testing is done
35%
Mosaicism
29.1%
Results may not represent embryo
25.2%
Clinical use of non-euploid embryos
20.4%
Level of mosaicism
18.4%
Miscarriage risk after PGT-A
17.5%

What predicted feeling supported

Share who felt supported, by whether the topic was discussed (or by country).

Level of mosaicism discussed
73.7%
Chance to discuss implications
71.1%
Representativeness discussed
65.4%
Clinical use discussed
61.9%
Risk of harm discussed
53.3%
Treated in the USA
32.5%

All differences shown were significant (p < 0.01). Logistic regression: opportunity to discuss implications OR 3.98 for feeling empowered; USA OR 0.218 for feeling informed; AUC 0.755.

Three themes in the open-text answers

Mismatched expectations

PGT-A was presented as more certain than it is. Some did not know it is not diagnostic or that mosaic results were possible.

“Just thought it was to sort good from bad.” #46

Inadequate information

Outcomes after transfer, mosaic categories, incidence and success rates went unaddressed. People educated themselves.

“The info was bad… I had to educate myself.” #9

An unsupported decision

Some had to self-advocate to secure a transfer, and some felt pressured to test.

“I stopped all IVF because of the trauma of having to fight to use my mosaics.” #54

What happened to those who transferred

43transferred a mosaic embryo and reported an outcome
93%clinical pregnancy (40/43)
86%ongoing pregnancy (37/43)

High-level mosaics did worse than low-level (clinical 87.5% vs 96%, ongoing 75% vs 91%), but the difference was not significant. A further 22 outcomes were pending. Of 43 yet to transfer, 58% planned to, 21% hoped to find a euploid embryo first, 14% were undecided and 7% gave other reasons. These are small, self-reported numbers, so treat them as description rather than evidence of effect.

What the authors recommend

For clinics

Put clinic policies on mosaic transfer into the consent form, and adopt the ESHRE recommendations.

For counselling

Offer standardised pre-test and post-test counselling by genetic counsellors or well-informed embryologists, plus psychological support.

Limits the authors note: only 0.8% of the group’s roughly 17,000 members responded (135), most respondents were White, educated and US-based, and treatment dates spanned 2016–2023, a period of rapid change. Source: Viñals Gonzalez et al., Hum Fertil 2024, doi:10.1080/14647273.2024.2431118. Casa Origen summarises research for information only; this is not medical advice.

Next
Next

Can NMN Boost Egg Quality?